Tag: Imatinib

The development of imatinib, the first approved tyrosine kinase inhibitor, revolutionized the treatment landscape for chronic myeloid leukemia (CML), transforming a fatal disease into a manageable chronic condition for many patients. This groundbreaking innovation introduced the world to the power of a **tinib drug**, a targeted medication ending in the suffix “-tinib.”

Originally approved in the early 2000s, imatinib—often known by brand names like Imanib and Gleevec—revolutionized the treatment landscape for certain cancers. A common question for many patients and caregivers is, **What is Imanib 400 mg used for?** It is a targeted therapy designed to block specific proteins that cause cancer cells to grow and multiply.

While it can seem confusing, the short answer is yes: Imatinib is the active drug ingredient in the medication branded and sold as Gleevec. This relationship is common in the pharmaceutical world, where a single chemical compound is known by its official generic name and by one or more brand names.